{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T06:12:02Z","timestamp":1695795122671},"reference-count":55,"publisher":"Wiley","issue":"S451","license":[{"start":{"date-parts":[[2007,1,2]],"date-time":"2007-01-02T00:00:00Z","timestamp":1167696000000},"content-version":"vor","delay-in-days":276,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acta Paediatrica"],"published-print":{"date-parts":[[2006,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This review describes the clinical characteristics of kidney disease in patients with diabetes in terms of functional and morphological changes, and summarizes the risk factors for progression of disease and the knowledge available today on various treatment modalities. New insights into the pathogenesis of kidney disease in diabetic patients are also reviewed in the context of the nephropathy of Fabry disease. Newly recognized pathways that play a role in the development\/progression of kidney disease in patients with diabetes include metabolic factors, (e.g. advanced glycation end products), intracellular signalling proteins (e.g. protein kinase C) and growth factors\/cytokines (e.g. growth hormone, insulin\u2010like growth factors, transforming growth factor \u03b2 and vascular endothelial growth factor). As classic examples of progress in our understanding of the pathogenesis of kidney disease in patients with diabetes, the relationship between two growth factor\/cytokine\u2010systems and the development of diabetic kidney disease is reviewed, including a description of well\u2010known or potential therapeutic strategies targeting the two systems.<\/jats:p><jats:p> <jats:bold>Conclusion:<\/jats:bold> It is hoped that the new pathogenetic insights into diabetic kidney disease may facilitate the development of new drugs for the treatment of this and related kidney diseases.<\/jats:p>","DOI":"10.1111\/j.1651-2227.2006.tb02396.x","type":"journal-article","created":{"date-parts":[[2010,8,7]],"date-time":"2010-08-07T01:23:10Z","timestamp":1281144190000},"page":"83-92","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Inhibition and reversibility of renal changes: lessons from diabetic kidney disease"],"prefix":"10.1111","volume":"95","author":[{"given":"Allan","family":"Flyvbjerg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,1,2]]},"reference":[{"key":"e_1_2_11_2_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.4.1258"},{"key":"e_1_2_11_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2000.00166.x"},{"key":"e_1_2_11_4_2","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","volume":"329","author":"The effect of intensive treatment of diabetes on the development and progression of long\u2010term complications in insulin\u2010dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group","year":"1993","journal-title":"N Engl J Med"},{"key":"e_1_2_11_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.290.16.2159"},{"key":"e_1_2_11_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2003.00712.x"},{"key":"e_1_2_11_7_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-134-5-200103060-00009"},{"key":"e_1_2_11_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011489"},{"key":"e_1_2_11_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011161"},{"key":"e_1_2_11_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011303"},{"key":"e_1_2_11_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021778"},{"key":"e_1_2_11_12_2","doi-asserted-by":"publisher","DOI":"10.1210\/er.2003-0018"},{"key":"e_1_2_11_13_2","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1210\/endo.141.4.7475","article-title":"Insulin\u2010like growth factor I receptor signaling\u2013overlapping or redundant pathways","volume":"141","author":"LeRoith D.","year":"2000","journal-title":"Endocrinology"},{"key":"e_1_2_11_14_2","doi-asserted-by":"publisher","DOI":"10.1210\/er.20.6.761"},{"key":"e_1_2_11_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001250051515"},{"key":"e_1_2_11_16_2","first-page":"398","article-title":"Progressive glomerulosclerosis develops in transgenic mice chronically expressing growth hormone and growth hormone releasing factor but not in those expressing insulinlike growth factor\u20101","volume":"131","author":"Doi T","year":"1988","journal-title":"Am J Pathol"},{"key":"e_1_2_11_17_2","first-page":"271","article-title":"Growth hormone and IGF\u2010I in diabetic children with and without microalbuminuria","volume":"12","author":"Verrotti A","year":"1999","journal-title":"Diabetes Nutr Metab"},{"key":"e_1_2_11_18_2","doi-asserted-by":"publisher","DOI":"10.1515\/JPEM.1997.10.2.209"},{"key":"e_1_2_11_19_2","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.2337\/diab.47.8.1341","article-title":"Contribution of growth hormone and IGF\u2010I to early diabetic nephropathy in type 1 diabetes","volume":"47","author":"Cummings EA","year":"1998","journal-title":"Diabetes"},{"key":"e_1_2_11_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001250051470"},{"key":"e_1_2_11_21_2","doi-asserted-by":"publisher","DOI":"10.1677\/joe.0.1590297"},{"key":"e_1_2_11_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00285295"},{"key":"e_1_2_11_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1992.124"},{"key":"e_1_2_11_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.1990.tb01394.x"},{"key":"e_1_2_11_25_2","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1001\/jama.1991.03460070070045","article-title":"Somatostatin analogue, octreotide, reduces increased glomerular filtration rate and kidney size in insulin\u2010dependent diabetes","volume":"265","author":"Serri O","year":"1991","journal-title":"JAMA"},{"key":"e_1_2_11_26_2","doi-asserted-by":"publisher","DOI":"10.1210\/en.141.1.163"},{"key":"e_1_2_11_27_2","doi-asserted-by":"publisher","DOI":"10.1210\/en.136.2.660"},{"key":"e_1_2_11_28_2","doi-asserted-by":"crossref","first-page":"5163","DOI":"10.1210\/endo.137.11.8895392","article-title":"A growth hormone antagonist protects mice against streptozotocin induced glomerulosclerosis even in the presence of elevated levels of glucose and glycated hemoglobin","volume":"137","author":"Chen NY","year":"1996","journal-title":"Endocrinology"},{"key":"e_1_2_11_29_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.48.2.377"},{"key":"e_1_2_11_30_2","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1681\/ASN.V11112027","article-title":"JB3, an IGF\u2010I receptor antagonist, inhibits early renal growth in diabetic and uninephrectomized rats","volume":"11","author":"Haylor J","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_11_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00403959"},{"key":"e_1_2_11_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/15.3.347"},{"key":"e_1_2_11_33_2","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.13.1.9"},{"key":"e_1_2_11_34_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.1998.274.3.H1054"},{"key":"e_1_2_11_35_2","first-page":"689","article-title":"Role for nitric oxide in the hyperpermeability and hemodynamic changes induced by intravenous VEGF","volume":"40","author":"Tilton RG","year":"1999","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_2_11_36_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.48.11.2229"},{"key":"e_1_2_11_37_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V1171236"},{"key":"e_1_2_11_38_2","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1998.8454"},{"key":"e_1_2_11_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001250051198"},{"key":"e_1_2_11_40_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-5491.2000.00350.x"},{"key":"e_1_2_11_41_2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/107602969900500105","article-title":"Elevated plasma vascular endothelial cell growth factor and thrombomodulin in juvenile diabetic patients","volume":"5","author":"McLaren M","year":"1999","journal-title":"Clin Appl Thromb Hemost"},{"key":"e_1_2_11_42_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-5491.2001.00476-2.x"},{"key":"e_1_2_11_43_2","doi-asserted-by":"publisher","DOI":"10.1203\/00006450-199812000-00008"},{"key":"e_1_2_11_44_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.57.s75.4.x"},{"key":"e_1_2_11_45_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-5491.2001.00441.x"},{"key":"e_1_2_11_46_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2000.00094.x"},{"key":"e_1_2_11_47_2","doi-asserted-by":"publisher","DOI":"10.1002\/path.1711770308"},{"key":"e_1_2_11_48_2","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1681\/ASN.V75661","article-title":"Fxpression of vascular permeability factor (VPF\/VEGF) is altered in many glomerular diseases","volume":"7","author":"Shulman K","year":"1996","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_11_49_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2001-19133"},{"key":"e_1_2_11_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1056-8727(02)00162-9"},{"key":"e_1_2_11_51_2","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1681\/ASN.V125993","article-title":"Hntibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes","volume":"12","author":"Vriese AS","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_11_52_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.51.10.3090"},{"key":"e_1_2_11_53_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2002.00310.x"},{"key":"e_1_2_11_54_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00007.2002"},{"key":"e_1_2_11_55_2","first-page":"99","article-title":"SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk\u20101\/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types","volume":"59","author":"Fong TA","year":"1999","journal-title":"Cancer Res"},{"key":"e_1_2_11_56_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001250051539"}],"container-title":["Acta Paediatrica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1651-2227.2006.tb02396.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1651-2227.2006.tb02396.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T10:51:04Z","timestamp":1695725464000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1651-2227.2006.tb02396.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4]]},"references-count":55,"journal-issue":{"issue":"S451","published-print":{"date-parts":[[2006,4]]}},"alternative-id":["10.1111\/j.1651-2227.2006.tb02396.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1651-2227.2006.tb02396.x","archive":["Portico"],"relation":{},"ISSN":["0803-5253","1651-2227"],"issn-type":[{"value":"0803-5253","type":"print"},{"value":"1651-2227","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,4]]},"assertion":[{"value":"2007-01-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}